Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer.

Autor: Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Kerkelä E; Finnish Red Cross Blood Service, Helsinki, Finland., Pasanen A; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Anttila M; Pathology, Finnish Food Authority, Helsinki, Finland., Tapper J; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland., Kanerva A; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. akseli.hemminki@helsinki.fi.

Publikováno v: Cancer gene therapy [Cancer Gene Ther] 2023 Dec; Vol. 30 (12), pp. 1679-1690. Date of Electronic Publication: 2023 Nov 10.

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.

Autor: Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Lähdeniemi IAK; Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLife, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Heiniö C; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Sutinen E; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland., Räsänen J; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Borenius K; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mäyränpää MI; Pathology, University of Helsinki and Helsinki University Hospital (HUSLAB), Helsinki, Finland., Aaltonen E; Faculty of Medicine, Medicum, University of Helsinki, Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Hemminki O; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Verschuren EW; Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLife, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Ilonen I; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.

Publikováno v: Oncoimmunology [Oncoimmunology] 2023 Aug 02; Vol. 12 (1), pp. 2241710. Date of Electronic Publication: 2023 Aug 02 (Print Publication: 2023).

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.

Autor: Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Girych M; Department of Physics, University of Helsinki, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Hamdan F; Laboratory of ImmunoViroTherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Hemmes A; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Heiniö C; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Kaptan S; Department of Physics, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Erikat A; Department of Chemistry and the Randall Centre for Cell and Molecular Biophysics, King's College London, London, United Kingdom., Schwartz J; Chicago Department of Oral Medicine and Diagnostic Science, University of Illinois, Chicago, IL, United States., Anttila M; Pathology, Finnish Food Authority, Helsinki, Finland., Aro K; Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland.; Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki Head and Neck Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Viitala T; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Vattulainen I; Department of Physics, University of Helsinki, Helsinki, Finland., Cerullo V; Laboratory of ImmunoViroTherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Kanerva A; Department of Gynecology and Obstetrics, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Feb 03; Vol. 14, pp. 1060540. Date of Electronic Publication: 2023 Feb 03 (Print Publication: 2023).

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.

Autor: Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Kononov A; Systems Oncology Group, Cancer research UK, Manchester University, Manchester, UK., Heiniö C; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Gladwyn-Ng I; Taconic Biosciences GmbH, Leverkusen, Germany., Aro K; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki Head and Neck Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Bäck L; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki Head and Neck Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Räsänen J; Department of Thoracic Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Ilonen I; Department of Thoracic Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Borenius K; Department of Thoracic Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Räsänen M; Department of Thoracic Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Hemminki O; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Rannikko A; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Tapper J; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.

Publikováno v: Oncoimmunology [Oncoimmunology] 2022 Jul 12; Vol. 11 (1), pp. 2096572. Date of Electronic Publication: 2022 Jul 12 (Print Publication: 2022).

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.

Autor: Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Heiniö C; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Anttila M; Pathology, Finnish Food Authority, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics, Helsinki, Finland., Kanerva A; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics, Helsinki, Finland.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Publikováno v: Oncoimmunology [Oncoimmunology] 2022 Jan 22; Vol. 11 (1), pp. 2028960. Date of Electronic Publication: 2022 Jan 22 (Print Publication: 2022).